Study of venetoclax and azacitidine for untreated AML patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial looks at how well the combination of venetoclax and azacitidine works for people with newly diagnosed AML who cannot have strong chemotherapy. It is a real-world study of patients already getting this treatment through a special program in France.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been newly diagnosed with acute myeloid leukemia (AML)
- Your doctor says you are not healthy enough for standard intensive chemotherapy
- You are receiving the combination of venetoclax and azacitidine (Ven-Aza) as your first AML treatment
- You have not had prior treatment for AML (except hydroxyurea or azacitidine started before venetoclax)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (tretinoin, azacitidine, and venetoclax) for people newly diagnosed with acute myeloid leukemia (AML) who have not yet received chemotherapy. The goal is to see if this combination can help control the leukemia.
This trial tests a combination of venetoclax and azacitidine for people with newly diagnosed acute myeloid leukemia (AML) who cannot have or choose not to have intensive chemotherapy. The goal is to see if adding a drug called cobicistat helps the treatment work better.
This study looks at how a standard AML treatment plan affects a person’s disease status over time. It focuses on newly diagnosed adults who cannot safely get intensive chemotherapy, using oral venetoclax plus azacitidine.
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
This Phase 2 trial compares two treatment approaches for people newly diagnosed with a specific type of AML (bone marrow cancer) that has an NPM1 mutation: venetoclax plus azacitidine versus intensive (strong) chemotherapy. It aims to see which plan works better and is safer for “fit” patients.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.